Researchers analysed the medical records of 1.6 million T2D patients who were either on GLP-1 medicines, insulin or metmorfim between March 2005 and November 2018, who had no previous history of obesity-related cancers.
However, semaglutide was not linked to a significantly reduced risk of developing thyroid, stomach or breast cancer, and the team found no significant decrease in cancer risk associated with GLP-1 RAs when compared with metformin.
Yoni Resnick, director of pharmacy clinical services, New England Cancer Specialists, said: “By offering this type of weight reduction medication as compared to other types of medications… you’re reducing the risk for cancer, thus improving the overall health of the population [and] cutting healthcare costs.”
Researchers intend to conduct more research, including pre-clinical and clinical trials, to build on these findings.
As well as cancer, diabetes drugs have also demonstrated benefits in reducing the risk of major adverse cardiovascular events (MACE) in patients with T2D, including stroke and heart disease.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.